Discontinuation of Antiresorptive Therapies: A Comparison between 1998–2001 and 2002–2004 among Osteoporotic Women

Abstract

Even if new dosing regimens were introduced, discontinuation of ART among osteoporotic women remains high.

Differences in persistence among different weekly oral bisphosphonate medications

“…Furthermore, the persistence with the generic formulations of alendronate appeared to be clinically and statistically lower than that of branded alendronate and branded risedronate. This findings are consistent with previous studies [27][28][29][30]. This important decrease in persistence to the generic formulations of alendronate could be due to the physicochemical characteristics of the generic tablets or to the characteristics of the patients to whom generics were dispensed.…”

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

“…Adherence to treatment is poor in all chronic diseases; osteoporosis is no exception [140]. There is some evidence that the response to treatment is suboptimal in those who adhere poorly [141,142].…”

Impact of a primary care physician workshop on osteoporosis medical practices

“…In Quebec, 94% of people aged ≥ 65 years are covered by the RAMQ for their medications [11]. These files have been validated for research [12] and are frequently used in pharmacoepidemiologic studies on osteoporosis [5,13,14].…”